Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SYNA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Gene Symbol | SYNA |
| Full Name | Synapsin I |
| Chromosome | 17q21.31 |
| Function | is a neuronal phosphoprotein associated with the cytoplasmic surface of synaptic vesicles. |
| Primary Expression | Brain (cortex, hippocampus, cerebellum), neurons |
| Subcellular Localization | presynaptic terminals where it associates with the cytoplasmic surface of synaptic vesicles. [@takamori2006] |
| Amino Acids | 706 aa |
| UniProt ID | P17600 |
| NCBI Gene ID | 6853 |
| Ensembl ID | ENSG00000135547 |
| OMIM | 313440 |
| GeneCards | SYNA |
| Human Protein Atlas | SYNA |
| Synapsin Ia | 706 amino acids |
| Synapsin Ib | 669 amino acids (lacking domain E) |
| KG Connections | 19 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
flowchart TD
N0["SYNA"]
N1["TFEB"]
N1 -->|"binds to"| N0
N2["neurodegeneration"]
N0 -->|"implicated in"| N2
classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
class N1 protein| Target | Relation | Type | Str |
|---|---|---|---|
| SPP1 | co_discussed | gene | 0.40 |
| DYSF | co_discussed | gene | 0.40 |
| C1QA | co_discussed | gene | 0.40 |
| GRN | co_discussed | gene | 0.40 |
| CTSB | co_discussed | gene | 0.40 |
| ALZHEIMER'S DISEASE | co_discussed | gene | 0.40 |
| PHAGOCYTOSIS | co_discussed | process | 0.40 |
| COMPLEMENT | co_discussed | pathway | 0.40 |
| LATE | co_discussed | disease | 0.40 |
| AMYLOID | co_discussed | gene | 0.40 |
| ANXIETY | co_discussed | gene | 0.40 |
| Source | Relation | Type | Str |
|---|---|---|---|
| TFEB | binds_to | protein | 0.90 |
| GNAL | co_discussed | gene | 0.40 |
| COMPLEMENT CASCADE | co_discussed | pathway | 0.40 |
| C1Q | co_discussed | gene | 0.40 |
| MICROGLIA | co_discussed | cell_type | 0.40 |
| NEUROINFLAMMATION | co_discussed | process | 0.40 |
| RNA | co_discussed | gene | 0.40 |
| NEUROINFLAMMATORY | co_discussed | pathway | 0.40 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Spp1 knockout prevents synaptic loss in AD mouse models | validation | Alzheimer's disease | 0.900 | 0.00 | Spp1 knockout AD mouse models | proposed | N/A |
| Synaptic plasticity and protein expression analysis in mPFC | exploratory | insomnia-anxiety comorbidity | 0.850 | 0.00 | mPFC brain slices from PCPA-tr | proposed | N/A |
| nSMase2 Inhibitor DPTIP Rescues Synaptic Density in APPswe/PS1deltaE9 | in_vivo | Alzheimer's disease | 0.803 | 0.74 | APPswe/PS1dE9 bigenic mice, 6- | proposed | $62,000 |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.509 | 0.50 | human postmortem brain tissue | proposed | $520,000 |
| s:** - Test whether HCN1 knockout specifically in EC layer II accelera | falsification | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| tACS Connectivity Trial in Early Alzheimer's | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Antidepressant effects of combined eucommia-gastrodia extract via modulation of [PMID:41921863] | Xue L, Pan Z, Liu Y, Gan Q, Liu D, Liu D | Brain research bulletin | 2026 | 0 |
| Complementary mechanisms of high-carbohydrate diets and ketogenic diets restore [PMID:41475465] | Kwon H, Seo DS, Ahmad Y, Park S, Yoo J, | The Journal of nutritional bio | 2026 | 0 |
| TrkB promotes the neuronal secretion of soluble Siglec-2 (CD22) to mitigate micr [PMID:41922794] | Shi X, Cai SZ, Chai JL, Xu CY, Zhou BY, | Molecular psychiatry | 2026 | 0 |
| The Potential Functions and Beneficial Effects of Melatonin on Cognitive Impairm [PMID:41917799] | Li XY, Cheng YZ, Zhang YM, Hu F, Fang SK | Brain and behavior | 2026 | 0 |
| Biomarkers for Alzheimer's disease across diverse biological domains: an umbrell [PMID:40680830] | Kang J, Son Y, Yim Y, Cho H, Kim J et al | J Adv Res | 2026 | 0 |
| Nanotherapeutic potential of Baicalein-encapsulated hUC-MSC exosomes in Alzheime [PMID:41370943] | Xu J, He Z, Pan Y, Cao B, Chen G | Biomater Adv | 2026 | 0 |
| Epigenetic mechanisms and therapeutic innovations in chronic pain-associated neu [PMID:41554641] | Zhang K, Zhu S, Xing N, Zhou Z, Chen J e | Br J Pharmacol | 2026 | 0 |
| Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinfl [PMID:41570486] | Lahariya R, Anand G, Kumari B, Priyadars | J Neuroimmunol | 2026 | 0 |
| miRNA-206 in muscle and central nervous system crosstalk during exercise: A doub [PMID:41571168] | Malvandi AM, Gerosa L, Maroni P, Orlando | Neurosci Biobehav Rev | 2026 | 0 |
| Experts' narrative review "Mastication, Hippocampal Structure Changes and Cognit [PMID:41576846] | Piancino MG | Arch Oral Biol | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| Plant-derived bioactive compounds modulate the gut microbiota in Alzheimer's dis [PMID:41678917] | Xue D, Hu X, Li R, Sun T, Qian S et al. | Phytomedicine | 2026 | 0 |
| Dysregulation of Drp1 and Mfn2 is associated with reduced PSD-95, synaptophysin, [PMID:41932483] | Alfateh M, Vasconcelos C, Choker AH, Moh | Int J Biol Macromol | 2026 | 0 |
| AICAR improves depression-like behaviors and is associated with hippocampal AMPK [PMID:41932583] | Takahashi K, Kurokawa K, Kawaguchi R, Ta | Neurochem Int | 2026 | 0 |
| Human umbilical cord mesenchymal stem cells therapy for Alzheimer's disease: a s [PMID:41847685] | Si C, Ma L, Ding W, Tian Y, Zhang J, Cao | Frontiers in neurology | 2026 | 0 |
| Cannabidiol and pBDNF Cotreatment Attenuates Pathological Symptoms and Improves [PMID:41924980] | Chaulagain B, Gothwal A, Mahanta AK, Jar | ACS chemical neuroscience | 2026 | 0 |
| Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerati [PMID:41868184] | Liu Z, Zhang H, Wan B, Yin S, Yue R | Drug design, development and t | 2026 | 0 |
| Modulation of mitochondrial quality by exercise mimetics: A potential strategy f [PMID:41804756] | Ke Z, Wang B, Liang R | Journal of Alzheimer's disease | 2026 | 0 |
| Neurotransmitter dysregulation in depression, anxiety, and suicidality: From syn [PMID:41924767] | K S V ABG, Verma AK, A SS, Sinha SS, Boy | Psychiatry research | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning SYNA in their description or question text
Score: 0.833 · synaptic-biology · 2026-04-28
This hypothesis proposes that the CREB-BDNF-TrkB activity-dependent signaling cascade directly controls the spatial posi
Score: 0.833 · synaptic-biology · 2026-04-21
**Molecular Mechanism and Rationale** The differential expression of complement regulators CD55 (decay-accelerating fac
Score: 0.820 · alzheimers · 2026-04-02
## Mechanistic Overview Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation starts from the cl
Score: 0.802 · lipidomics · 2026-04-25
The hypothesis proposes that ω-3 docosahexaenoic acid (DHA) is metabolized by CYP2J2 to generate protective epoxides tha
Score: 0.776 · neurodegeneration · 2026-04-16
## Mechanistic Overview CX3CR1-TREM2 Integration for Synapse Pruning Normalization starts from the claim that modulating
Score: 0.769 · neurodegeneration · 2026-04-26
C1q (classical complement cascade initiator) is upregulated in AD brain and tags synapses for microglial phagocytosis vi
Score: 0.763 · neurodegeneration · 2026-04-02
## Mechanistic Overview SASP-Mediated Cholinergic Synapse Disruption starts from the claim that modulating MMP2/MMP9 wit
Score: 0.754 · alzheimers · 2026-04-07
## Mechanistic Overview Closed-loop focused ultrasound targeting CA1 PV interneurons to restore theta-gamma coupling and
Score: 0.750 · neurodegeneration · 2026-04-25
The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway
Score: 0.740 · neurodegeneration · 2026-04-15
## **Molecular Mechanism and Rationale** The molecular basis for MEF2C-dependent synaptic gene regulation centers on a
Score: 0.738 · neurodegeneration · 2026-04-26
Specific combinations of tau phosphorylation, acetylation, and truncation mark assemblies that evade degradation and tem
Score: 0.724 · neurodegeneration · 2026-04-13
**Molecular Mechanism and Rationale** The molecular cascade underlying TBK1 loss-of-function-mediated synapse eliminati
Score: 0.721 · neurodegeneration · 2026-04-02
## Mechanistic Overview Sleep Spindle-Synaptic Plasticity Enhancement starts from the claim that modulating CACNA1G with
Score: 0.720 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The complement cascade represents a critical innate immune system that, when dysr